Sorrento Therapeutics (SRNE)
(Delayed Data from OTC)
$0.02 USD
0.00 (7.14%)
Updated May 3, 2024 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Sorrento Therapeutics, Inc. [SRNE]
Reports for Purchase
Showing records 141 - 160 ( 185 total )
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
One Stop Shopping for Cutting Edge Assets; Initiating at Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent Developments Bode Well for Sorrento; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent Developments Bode Well for Sorrento; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sorrento Inks Servier Anti-PD-1 Partnership; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sorrento Inks Servier Anti-PD-1 Partnership; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Executes Letter Agreement; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sorrento Executes Letter Agreement; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
$150M Private Placement Closed; 3SBio Joint Venture Announced; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
$150M Private Placement Closed; 3SBio Joint Venture Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Financing Overhang Removed; Reiterate Buy and Reducing Price Target to $30
Provider: Rodman & Renshaw, Co.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Financing Overhang Removed; Reiterate Buy and Reducing Price Target to $30
Provider: H.C. Wainwright & Co., Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Strategic Evolution Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Strategic Evolution Continues; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Yuhan Joint Venture Established; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Yuhan Joint Venture Established; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Evolution Continues at Sorrento; Reiterate Buy and Modulating Price Target to $40 Per Share
Provider: H.C. Wainwright & Co., Inc.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Evolution Continues at Sorrento; Reiterate Buy and Modulating Price Target to $40 Per Share
Provider: Rodman & Renshaw, Co.
Company: Sorrento Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2016 Healthcare Sector Outlook: Year Ahead Perspectives
Provider: H.C. Wainwright & Co., Inc.